-transparent.png){kind=logo}
The ability of cis-dichlorodiammine platinum II to cause chromosomal aberrations in rats and dominant lethality in mice was studied. Five daily intraperitoneal doses ranging from 0.25 to 2.00 mg/kg/day failed to result in the observance of dominant lethal mutations in mice. Intraperitoneal doses of 0.13 and 0.52 mg/kg/day for 5 days in rats did, however, cause chromosomal aberrations in bone marrow cells collected and harvested 24 h after the last dose. The incidence of total aberrations observed at the 0.52 mg/kg/day dose level was 5.5-fold greater than that seen for the vehicle control group. Thus, cis-dichlorodiammine platinum II appears to be clastogenic in rats.
Related Publications
B S Levine, and
M M Preache, and
E Pergament
September 1979,
Mutation research,
B S Levine, and
M M Preache, and
E Pergament
April 1978,
Clinical pharmacology and therapeutics,
B S Levine, and
M M Preache, and
E Pergament
June 1979,
The Medical journal of Australia,
B S Levine, and
M M Preache, and
E Pergament
January 1982,
Therapeutic drug monitoring,
B S Levine, and
M M Preache, and
E Pergament
October 1989,
Artificial organs,
B S Levine, and
M M Preache, and
E Pergament
January 1983,
American journal of otolaryngology,
B S Levine, and
M M Preache, and
E Pergament
October 1994,
The Journal of biological chemistry,
B S Levine, and
M M Preache, and
E Pergament
August 1975,
Toxicology and applied pharmacology,
B S Levine, and
M M Preache, and
E Pergament
August 1987,
Gan to kagaku ryoho. Cancer & chemotherapy,
B S Levine, and
M M Preache, and
E Pergament
December 1980,
Research communications in chemical pathology and pharmacology,
